The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
Authors
Keywords
-
Journal
DIABETOLOGIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-18
DOI
10.1007/s00125-021-05529-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
- (2020) Salim S. Virani et al. CIRCULATION
- Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
- (2020) Tanya Wilcox et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes
- (2020) Apostolos Tsapas et al. ANNALS OF INTERNAL MEDICINE
- Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
- (2020) Alexandros Sachinidis et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
- (2019) Yue Fei et al. Cardiovascular Diabetology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis
- (2019) Kevin Bryan Lo et al. CardioRenal Medicine
- Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association
- (2018) Annabelle Santos Volgman et al. CIRCULATION
- The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
- (2018) Jonathan D. Newman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Racial and Ethnic Differences in Acute Coronary Syndrome and Myocardial Infarction Within the United States: From Demographics to Outcomes
- (2016) Garth Graham CLINICAL CARDIOLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
- (2015) Theo Vos et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conceptual and Technical Challenges in Network Meta-analysis
- (2013) Andrea Cipriani et al. ANNALS OF INTERNAL MEDICINE
- The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE−/− mouse model
- (2013) Tracey Gaspari et al. Diabetes & Vascular Disease Research
- Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes
- (2013) Susan Herzlinger et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience
- (2013) William R. Hiatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005
- (2009) Sarah Rosner Preis et al. CIRCULATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now